What is Terrestrial Bio?
Terrestrial Bio operates at the intersection of biotechnology and patient-centric engineering. The company is the developer of the Tacterra microarray patch, a sophisticated platform designed to facilitate the needle-free, self-administration of complex biologics. By utilizing dissolvable microarray technology, Terrestrial Bio addresses critical bottlenecks in modern medicine, including the need for cold-chain logistics and the inherent discomfort associated with traditional injection methods. This technology not only simplifies the patient experience but also expands the reach of advanced therapeutics into decentralized care settings, positioning the company as a critical infrastructure provider in the next generation of drug delivery.
How much funding has Terrestrial Bio raised?
Terrestrial Bio has raised a total of $57.3M across 1 funding round:
Stock/Share Issuance
$57.3M
Stock/Share Issuance (2026): $57.3M, investors not publicly disclosed
Key Investors in Terrestrial Bio
Terrestrial Bio
Undisclosed investor participating in the funding round.
What's next for Terrestrial Bio?
With the infusion of this major enterprise-level funding, Terrestrial Bio is expected to transition from clinical validation to large-scale manufacturing and market penetration. The strategic roadmap likely involves scaling the Tacterra platform to accommodate a broader range of therapeutic molecules and establishing partnerships with global pharmaceutical entities. As the company matures, the focus will shift toward regulatory milestones and the optimization of supply chain efficiencies to support the global distribution of its needle-free solutions. Investors will be monitoring the firm's ability to integrate its technology into existing clinical workflows and its success in securing long-term supply agreements with major drug developers.
See full Terrestrial Bio company page
